Clinical trials: Acne Vulgaris
Acne
Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne Vulgaris
The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe…
- Trial name
- NCT02932306
- Testing
- IDP-121 Lotion, IDP-121 Vehicle Lotion
- Where
- 39 sites in United States
- Volunteers
- 820 people
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Participants With Acne Vulgaris
study designed to assess the safety, tolerability, and efficacy of IDP-120 Gel and IDP-120 Vehicle Gel
- Trial name
- NCT03664752
- Testing
- IDP-120 Gel, IDP-120 Vehicle Gel
- Where
- 20 sites in United States, Canada
- Volunteers
- 585 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe…
- Trial name
- NCT05080764
- Testing
- 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Biofrontera Inc.
Acne Vulgaris
A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients
The etiology of acne is heavily dependent on the production of sebum by the sebaceous glands that results in the growth of the bacteria c. acnes. If no sebum is present, there is no nutritional source for the c.
- Trial name
- NCT06415279
- Testing
- Winlevi (clascoterone) 1% cream
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Acne Vulgaris
Laser Treatment of Moderate to Severe Acne Vulgaris
The goal of this clinical trial is to learn if fractional ablative laser can treat active acne vulgaris in adults 18 to 40 years old with moderate to severe acne vulgaris.
- Trial name
- NCT04466527
- Testing
- Laser Intervention
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Massachusetts General Hospital
Acne Vulgaris
A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
Acne vulgaris is the most common skin disease in patients with skin of color and second most common in Caucasian population. The global prevalence is thought to be as high as 60-80% in individuals 12-25 years of age.
- Trial name
- NCT06415305
- Testing
- Winlevi (clascoterone) 1% cream
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Acne Vulgaris
Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel
The safety and efficacy of once daily application of IDP 126 Gel will be compared to Epiduo® Forte and IDP-126 Vehicle Gel.
- Trial name
- NCT04892706
- Testing
- IDP-126 Gel, IDP-126 Vehicle Gel, Epiduo® Forte Gel
- Where
- 42 sites in United States, Belgium and 1 more
- Volunteers
- 686 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne
Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Adapalene 0.3% gel in…
- Trial name
- NCT06336603
- Testing
- Winlevi (clascoterone) 1% & Adapalene 0.3% gel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Acne Vulgaris
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris
- Trial name
- NCT04856917
- Testing
- Imsidolimab
- Where
- 15 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- Vanda Pharmaceuticals
Acne
A Pilot Clinical Trial Investigating the Effect of Cutaneous Cooling on Sebum Production
To evaluate the safety and feasibility of reducing human sebum production using the ZELTIQ System.
- Trial name
- NCT01686841
- Testing
- The Zeltiq System
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Acne Vulgaris
A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne
Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Duac gel in combination…
- Trial name
- NCT06336629
- Testing
- Winlevi (clascoterone) 1% & Duac gel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
This project, "A double-blind placebo-controlled randomized clinical trial assessing the efficacy of metformin for hepatic fat in adolescents and young adults with polycystic ovary syndrome", proposes exploring the use of novel…
- Conditions
- Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- NCT02500147
- Testing
- Metformin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Acne Vulgaris
Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris
The aim of this proof of principle study is to evaluate efficacy and safety of the sequential application of two marketed products for the treatment of acne vulgaris, using the Split-Face model
- Trial name
- NCT01461655
- Testing
- marketed topical retinoid, marketed topical NSAID, vehicle gel
- Where
- France
- Volunteers
- 40 people
- Sponsor
- LEO Pharma
Acne Vulgaris
Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne
An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled, double-blinded, split-pace (left/right) design trial to evaluate the efficacy and tolerability of LEO 43204 in adults with moderate to severe…
- Trial name
- NCT02575950
- Testing
- LEO43204
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- LEO Pharma
Acne Vulgaris
A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients
Acne medications are a common source of facial dryness resulting in skin barrier damage and poor patient compliance. Retinoids and benzoyl peroxide are some of the most frequently prescribed and effective acne medications…
- Trial name
- NCT06415292
- Testing
- Winlevi (clascoterone) 1% cream
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Acne, Scars
Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar.
The scope of this open label clinical trial is to evaluate and confirm the performance of Papix acne scar in the prevention and improvement of acne scars in subject suffering for mild to moderate acne.
- Trial name
- NCT04806594
- Testing
- Papix acne scar
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Relife S.r.l.
Acne Scars - Mixed Atrophic and Hypertrophic, Acne
Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring
This single-center, clinical trial consists of a one autologous fat grafting treatment followed by 3-month and 6-month post-treatment visits in order to assess the efficacy of fat grafting when used by men and women with facial…
- Trial name
- NCT04559022
- Testing
- Fat Grafting
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Acne Vulgaris
Evaluation of Efficacy and Tolerance of Crystal Peel in the Treatment of Adults Presenting Facial Mild Acne
The goal of this interventional, confirmatory and post market study is to evaluate the efficacy and clinical performance of Crystal Peel in adults suffering mild facial acne vulgaris.
- Trial name
- NCT05821296
- Testing
- Crystal Peel
- Where
- Poland
- Volunteers
- 42 people
- Sponsor
- Dermosciences France
Acne Vulgaris
Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)
The purpose of this study is to evaluate the patient-reported outcomes (PROs) in terms of health-related quality of life (HRQoL) and signs of Acne Vulgaris (AV) among patients with moderate to severe non-nodular AV who are…
- Trial name
- PROSES (NCT04820673)
- Testing
- Sarecycline
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.
- Trial name
- NCT05550337
- Testing
- Trifarotene 0.005 % Topical Cream, AKLIEF®
- Where
- 14 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA